Swiss Roche cancer drugs will be packaged in Ukraine
Ukraine has signed an agreement with the Swiss pharmaceutical giant Roche (F. Hoffmann-La Roche) on the localization of production of drugs for lung and breast cancer. The document was signed during the Ukraine Recovery Conference 2025 in Rome, the press service of the state-owned enterprise Medical Procurement of Ukraine (MPU) reported.
The investment agreement provides for the supply of medicines in bulk, i.e. in a ready-to-package form, and their packaging, final packaging and labeling will be carried out directly in Ukraine.
For this purpose, the project envisages the construction of production facilities on the basis of the branch of the Ministry of Healthcare of Ukraine "Medsuppliment", obtaining a license for production and staff training.
Under the agreement, F. Hoffmann-La Roche will supply two drugs to Ukraine:
→ atezolizumab (trade name Tecentriq) – used, in particular, to treat the most common type of lung cancer;
→ pertuzumab in combination with trastuzumab (trade name Fesgo) – used to treat HER2-positive breast cancer.
The final implementation of the project is scheduled for 2027. Then the first patients should receive medicines that have passed the final stages of production in Ukraine.
Roche estimates that the agreement will provide innovative medicines to more than 5,800 patients over five years. At the same time, the cost of these drugs will be significantly lower than the current one due to the implementation of the final stages of production in Ukraine.
- F. Hoffmann-La Roche Ltd (commonly known as Roche) is a global leader in innovative pharmaceuticals and diagnostics. Founded in 1896 in Basel, Switzerland, Roche has more than 100,000 employees in more than 100 countries .